Drug Profile
Camptothecin liposomal - Aphios
Alternative Names: Camposomes; Liposome encapsulated camptothecinLatest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator Aphios Corporation
- Class Antineoplastics; Camptothecins; Drug conjugates; Small molecules
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Pancreatic cancer
- Discontinued Colorectal cancer
Most Recent Events
- 25 Nov 2021 Discontinued - Preclinical for Colorectal cancer in USA (IV) in November 2021 (Aphios Corporation pipeline, November 2021)
- 08 Apr 2021 Preclinical development is still ongoing for colorectal cancer and Pancreatic cancer in USA (Aphios Corporation website, April 2021)
- 01 Apr 2021 Preclinical trials in Pancreatic cancer in USA (IV) before April 2021 (Aphios Corporation website, April 2021)